LivaNova (NASDAQ:LIVN) Stock: Insider Alex Shvartsburg Sells 2,500 Shares

LivaNova PLC (NASDAQ:LIVN – Get Free Report) CFO Alex Shvartsburg sold 2,500 shares of the company’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $90.91, for a total transaction of $227,275.00. Following the sale, the chief financial officer owned 42,147 shares in the company, valued at $3,831,583.77. The trade was a 5.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

LivaNova Stock Up 1.2%

NASDAQ:LIVN traded up $1.12 during mid-day trading on Friday, hitting $91.32. The stock had a trading volume of 742,276 shares, compared to its average volume of 764,040. LivaNova PLC has a twelve month low of $52.37 and a twelve month high of $99.38. The stock has a 50-day simple moving average of $80.32 and a two-hundred day simple moving average of $74.22. The company has a current ratio of 1.46, a quick ratio of 1.22 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $5.03 billion, a PE ratio of 30.44 and a beta of 0.91.

LivaNova (NASDAQ:LIVN – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.06 by $0.17. LivaNova had a net margin of 13.01% and a return on equity of 16.10%. The company had revenue of $393.15 million during the quarter, compared to analysts’ expectations of $381.13 million. During the same quarter in the previous year, the business posted $1.11 EPS. The firm’s revenue was up 9.9% on a year-over-year basis. On average, equities research analysts anticipate that LivaNova PLC will post 3.76 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on LIVN shares. Stifel Nicolaus set a $85.00 target price on shares of LivaNova in a research note on Wednesday, August 5th. Robert W. Baird raised their price target on LivaNova from $95.00 to $111.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Zacks Research downgraded LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Barclays lifted their price target on LivaNova from $105.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, November 9th. Finally, Weiss Ratings raised LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, October 27th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $101.22.

Get Our Latest Stock Analysis on LIVN

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently bought and sold shares of LIVN. Allworth Financial LP boosted its stake in LivaNova by 93.5% in the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. Root Financial Partners LLC acquired a new stake in shares of LivaNova during the third quarter worth about $32,000. Farther Finance Advisors LLC lifted its holdings in shares of LivaNova by 59.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock valued at $35,000 after purchasing an additional 169 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of LivaNova in the 2nd quarter valued at about $37,000. Finally, Bessemer Group Inc. lifted its holdings in shares of LivaNova by 27.8% in the 3rd quarter. Bessemer Group Inc. now owns 520 shares of the company’s stock valued at $40,000 after purchasing an additional 113 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

(Get Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.

Recommended Stories

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.